Bioventus Inc.
BVS
$6.55
$0.121.87%
NASDAQ
| 03/29/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -19.37% | 10.56% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -19.37% | 10.56% | |||
| Cost of Revenue | -19.94% | 12.27% | |||
| Gross Profit | -19.09% | 9.73% | |||
| SG&A Expenses | -15.08% | 6.78% | |||
| Depreciation & Amortization | -9.90% | -14.38% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.58% | 7.71% | |||
| Operating Income | -55.24% | 67.38% | |||
| Income Before Tax | -1,572.84% | 104.80% | |||
| Income Tax Expenses | -117.27% | -6.62% | |||
| Earnings from Continuing Operations | -944.65% | 94.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 322.84% | -72.86% | |||
| Net Income | -1,590.38% | 96.77% | |||
| EBIT | -55.24% | 67.38% | |||
| EBITDA | 5.93% | -15.96% | |||
| EPS Basic | -1,562.50% | 96.75% | |||
| Normalized Basic EPS | -160.87% | 373.81% | |||
| EPS Diluted | -1,562.50% | 96.75% | |||
| Normalized Diluted EPS | -160.87% | 373.81% | |||
| Average Basic Shares Outstanding | 0.85% | 0.30% | |||
| Average Diluted Shares Outstanding | 0.85% | 0.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||